Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

ALNY

Alnylam Pharmaceuticals Inc

NASDAQ

145.16

-0.16

-0.11%

Closed 16:31 04/18 EDT

OPEN

145.00

PREV CLOSE

145.32

HIGH

146.47

LOW

144.23

VOLUME

398.91K

TURNOVER

52 WEEK HIGH

218.88

52 WEEK LOW

143.52

MARKET CAP

18.28B

P/E (TTM)

-41.1848

Health Rounds: Urine tests finds worrisome prostate cancer, avoids unneeded biopsies

Health Rounds: Urine tests finds worrisome prostate cancer, avoids unneeded biopsies. A urine test detects prostate cancer in of treatment more accurately than standard blood tests. A single injection of an experimental drug for people with hard-to-control high blood pressure. The other is a urine test for detecting prostate cancer that may reduce the for biopsy.

Reuters · 1d ago

Guru Fundamental Report for ALNY - Benjamin Graham

NASDAQ · 1d ago

Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results on Thursday, May 2, 2024. The Company will report financial results for the first quarter ending March 31, 2024 before the U.S. Financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results via conference call. Alnylam is the leading RNAi therapeutics company.

Dow Jones · 1d ago

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability

Alnylam Pharmaceuticals, Inc. Posted a loss of US$440m in its most recent financial year. The biopharmaceutical company is expected to grow at an average annual rate of 61% to become profitable. The company is predicted to turn a profit in 2026. It currently has negative equity on its balance sheet. We look at the expectations for the company's growth and when analysts expect it to be profitable.

Simply Wall St · 4d ago

Weekly Report: what happened at ALNY last week (0408-0412)?

Weekly Report · 4d ago

Wolfe upgrades Ionis to outperform, cites upcoming catalysts

Seeking Alpha · 04/10 16:03

Buy Rating Affirmed for Alnylam Pharma on Strong Zilebesiran Trial Results and Lucrative Roche Partnership

TipRanks · 04/09 14:25

Alnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic Partnerships

TipRanks · 04/09 11:15

About ALNY

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.